The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult patients with cancer with advanced solid tumors.
A. Thomas-Schoemann
No relevant relationships to disclose
M. Tod
No relevant relationships to disclose
O. Mir
Consultant or Advisory Role - Roche (U); SERVIER (U)
N. Bancelin
No relevant relationships to disclose
R. Coriat
No relevant relationships to disclose
F. Taieb
No relevant relationships to disclose
P. Boudou-Rouquette
No relevant relationships to disclose
H. Abbas
No relevant relationships to disclose
S. Ropert
Consultant or Advisory Role - Roche (U)
J. Durand
No relevant relationships to disclose
A. Dauphin
No relevant relationships to disclose
F. Goldwasser
Consultant or Advisory Role - Amgen (U); Bayer (U); Roche (U)
B. Blanchet
No relevant relationships to disclose